Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Aldesleukin in Aggressive NHL
NCT00250861Phase 2Terminated
- Sponsor
- US Oncology Network
- Start
- Oct 2005
- Primary completion
- Aug 2007
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised trial of aldesleukin in B-cell non-Hodgkin lymphoma (2 arms), sponsored by US Oncology Network. Primary endpoint: Risk of cancer returning. Started Oct 2005; status: terminated.
02
Drugs
aldesleukin
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00250861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00250861.